Search Results

[Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].

• Authors : Vorobyev VI; Botkin Moscow City Clinical Hospital.; Gemdzhian EG

Subjects: Antineoplastic Combined Chemotherapy Protocols* ; Hematopoietic Stem Cell Transplantation*; Lymphoma, Mantle-Cell/Lymphoma, Mantle-Cell/Lymphoma, Mantle-Cell/*therapy

• Source: Terapevticheskii arkhiv [Ter Arkh] 2019 Jul 15; Vol. 91 (7), pp. 41-51. Date of Electronic Publication: 2019 Jul 15.Publisher: ZAO 'Konsilium Medikum Country of Publication: Russia (Federation) NLM ID: 2984818R Publication Model: Electronic Cited Medium: Print

Record details

[THE MECHANISMS OF ACTION OF RITUXIMAB].

• Authors : Gil'deeva GN; Kudlai DA; Luk'yanov SV

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*therapeutic use ; Arthritis, Rheumatoid/Arthritis, Rheumatoid/Arthritis, Rheumatoid/*drug therapy

• Source: Eksperimental'naia i klinicheskaia farmakologiia [Eksp Klin Farmakol] 2015; Vol. 78 (12), pp. 51-6.Publisher: Izd-vo Meditsina Country of Publication: Russia (Federation) NLM ID: 9215981 Publication Model: Print Cited Medium: Print ISSN:

Record details

[Hepatitis C virus-associated cryoglobulinemic vasculitis: A 20-year experience with treatment].

• Authors : Ignatova TM; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia; V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia.

Subjects: Cryoglobulinemia*/Cryoglobulinemia*/Cryoglobulinemia*/diagnosis ; Cryoglobulinemia*/Cryoglobulinemia*/Cryoglobulinemia*/etiology ; Cryoglobulinemia*/Cryoglobulinemia*/Cryoglobulinemia*/physiopathology

• Source: Terapevticheskii arkhiv [Ter Arkh] 2017; Vol. 89 (5), pp. 46-52.Publisher: ZAO 'Konsilium Medikum Country of Publication: Russia (Federation) NLM ID: 2984818R Publication Model: Print Cited Medium: Print ISSN:

Record details

ТЕРАПЕВТИЧНА ЕФИКАСНОСТ И РАЗХОДНА ЕФЕКТИВНОСТ НА IBRUTINIB/RITUXIMAB, IBRUTINIB/OBINUTUZUMAB И VENETOCLAX/OBINUTUZUMAB ЗА ЛЕЧЕНИЕ НА ПАЦИЕНТИ С ХРОНИЧНА ЛИМФОЦИТНА ЛЕВКЕМИЯ – МРЕЖОВ МЕТААНАЛИЗ.

• Authors : Веков, Т.; Чилингирова, Н.; Велева, Н.

• Source: Medical Review / Meditsinski Pregled; 2021, Vol. 57 Issue 4, p44-50, 7p

Record details

Застосування ритуксимабу в лікуванні дітей з нефротичним синдромом.

• Authors : Л. І., Вакуленко; О. М., Литвинова; І. В., Посмітюха

• Source: Pocki; 2022, Vol. 11 Issue 2, p86-91, 6p

Record details

Менеджмент рефрактерного волчаночного нефрита: сложности и возможности

• Authors : Головач, И. Ю.; Егудина, Е. Д.

• Source: Pocki; 2020, Vol. 9 Issue 1, p47-57, 11p

Record details

ПРЕПОРЪКИ НА ЕВРОПЕЙСКАТА ГРУПА ЗА ИЗУЧАВАНЕ НА ТИРЕОИД-АСОЦИИРАНАТА ОФТАЛМОПАТИЯ (EUGOGO) - НОВОСТИ В ЛЕЧЕНИЕТО ОТ 2021 Г

• Authors : Боянова, М.

• Source: Endocrine Diseases; 2022, Vol. 51 Issue 1, p13-27, 15p

Record details

Лечение на честорецидивиращ и кортико-зависим нефротичен синдром в детската възраст.

• Authors : Златанова, Г.; Гайдарова, М.; Русинов, Д.

• Source: Pediatria; 2020, Vol. 60 Issue 4, p45-48, 4p

Record details

Иммунобиологические препараты в терапии ревматических заболеваний

• Authors : Мельник, А. А.

• Source: Pocki; 2019, Vol. 8 Issue 3, p174-188, 15p

Record details

[State-of-the-art paradigm of corticosteroid therapy for immune-mediated inflammatory kidney diseases].

• Authors : Bulanov NM; Sechenov First Moscow State Medical University (Sechenov University).; Bobkova IN

Subjects: Immunosuppressive Agents*/Immunosuppressive Agents*/Immunosuppressive Agents*/adverse effects ; Glomerulonephritis, IGA*; Humans

• Source: Terapevticheskii arkhiv [Ter Arkh] 2023 Aug 17; Vol. 95 (6), pp. 451-456. Date of Electronic Publication: 2023 Aug 17.Publisher: ZAO 'Konsilium Medikum Country of Publication: Russia (Federation) NLM ID: 2984818R Publication Model: Electronic Cited Medium: Print

Record details